David Heal will be participating in the 63rd Annual Meeting of the ACNP (American College of Neuropsychopharmacology) to be held at the JW Marriott Desert Ridge Resort & Spa, Phoenix, Arizona, USA, 8th-11th December 2024.
Our latest publication evaluates the growing evidence from non-clinical and clinical studies for the anti-inflammatory and antioxidant effects of phytocannabinoids and assesses their potential to be efficacious treatments for neuroinflammatory disorders.
David Heal will be attending the Safety Pharmacology Society Annual Meeting to be held at the Town and Country Resort, San Diego, California, USA, 22nd to 25th September 2024.
DevelRx are pleased to announce a new PhD studentship with the University of Bristol. The student, Katie Kamenish, started in March 2024 and is studying the emotional and reinforcing properties of novel opioid ligands for the treatment of pain.
If you are developing novel cannabinoid-based drugs for therapeutic use you may be interested in our recent critical evaluation of the abuse and dependence and associated safety risks of botanically-derived and chemically-synthesized cannabinoid compounds.
One of the Directors of DevelRx, David Heal, will be participating in the 86th Annual Meeting of the College on Problems of Drug Dependence to be held at Fairmont The Queen Elizabeth Hotel in Montreal, Quebec, Canada, 15th-19th June, 2024.
David Heal has been accepted as an in-person participant at the European Medicines Agency (EMA) meeting ‘EMA multi-stakeholder workshop on psychedelics – Towards an EU regulatory framework’ to be held at the EMA, Amsterdam, The Netherlands, 16th-17th April 2024.
We are pleased to announce that our latest review on the use of stimulant prodrugs to treat attention deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED) has recently been published.
David Heal and Eloise Kuijer, our PhD student with Chris Bailey, Sarah Bailey and Sue Wonnacott of the Department of Life Sciences, University of Bath, will be presenting posters at the 62nd Annual Meeting of the American College of Neuropsychopharmacology, 3rd to 6th December, 2023, to be held at JW Marriott Tampa Water Street, Tampa, Florida, USA.
Congratulations to Sharon Smith, one of our Executive Directors, who has recently been voted onto the Editorial Board of the Journal of Psychopharmacology - a fully peer-reviewed, international journal publishing original scientific papers and reviews on preclinical and clinical psychopharmacology.
David Heal has been invited to speak at this meeting, organised by CCALC (Cross-Company Abuse Liability Council) and the FDA. It will be held on 27-28th September 2023 at the Hilton Washington DC Hotel in Rockville, MD, USA.
David Heal, one of our Directors, and Clare Stanford, University College London, have written a chapter in the Handbook of Experimental Pharmacology describing how modulation of the function of specific adrenoceptor subtypes contributes to the efficacy and safety of drugs for the treatment of psychiatric disorders.
It provides a comprehensive overview of the extraordinary progress in basic and clinical research on psychedelic drugs made during the past five years.
Part of the mission of DevelRx is to support academic science in the UK. Since the inauguration of DevelRx in 2020, we have collaborated with the University of Bath by supporting PhD programmes and undergraduate and post-graduate teaching.
Congratulations to Eloise Kuijer, our PhD student with Dr Chris Bailey, Professor Sue Wonnacott and Dr Sarah Bailey, Department of Life Sciences, University of Bath, who has been invited to take part in a symposium sponsored by the British Pharmacological Society on ‘GPCRs in addiction’ on 5th July 2023 at the 19th World Congress of Basic and Clinical Pharmacology to be held at the Scottish Event Campus in Glasgow.
DevelRx will be participating in the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence to be held at the Sheraton Denver Downtown Hotel, Denver, Colorado, USA, 17th-21st June, 2023. If you are developing novel centrally-acting compounds and would like to learn more about our services come along and meet us at one of our posters.
We have recently had our first book chapter published in Mandarin Chinese. The article on abuse and dependence testing procedures is in a book on safety pharmacology that was written to support drug safety evaluations in China and other Asian countries.
This paper outlines strategies for the non-clinical and clinical evaluation of the abuse potential of psychedelics, ie serotonergic hallucinogens and entactogens for new drug applications to the FDA and scheduling recommendations.
We are pleased to announce that our application for a 50 : 50 DevelRx : University Research Studentship Award (URSA) funded PhD studentship with the University of Bath has been accepted.
If you are developing opioid antagonists for therapeutic use, it is important to use non-clinical studies to profile the effects of the compounds at mu, kappa and delta opioid receptors to confirm mode of action and evaluate the potential for adverse side effects associated with agonist activity at opioid receptors.
Eloise Kuijer, our PhD student with the University of Bath, will be presenting the results of her research into the effects of activating kappa opioid receptors at KappaCon 2023
Our latest paper describing screening strategies for drug discovery and development to deliver more effective and safer psychedelics and entactogens for clinical use is now available online
Congratulations to David Heal on being elected an Honorary Fellow of the British Pharmacological Society for sustained excellence in research, including drug discovery and development
David Heal will be attending the 61st Annual Meeting of the ACNP (American College of Neuropsychopharmacology), 4th to 7th December 2022, JW Marriott Desert Ridge Resort and Spa, Phoenix, Arizona. If you would like to see David at the ACNP to discuss our consultancy services in the areas of drug abuse evaluation and CNS and metabolic disorders please contact inform@develrx.com.